CJC-1295 and ipamorelin dosage calculator: how the math works

Last updated 2026-07-24

What does a CJC-1295/ipamorelin dosage calculator actually calculate?

It does one job: unit conversion. You put in three numbers (total peptide in the vial, in mg; the amount of bacteriostatic water you added, in mL; and your target dose, in mcg or mg) and it spits out how many mL, or which mark on an insulin syringe, corresponds to that dose. That's it. It's a ratio calculation, not a medical recommendation. The formula underneath is: concentration (mcg/mL) = total peptide (mcg) ÷ total diluent volume (mL). Then: injection volume (mL) = target dose (mcg) ÷ concentration (mcg/mL). If you mix a 5 mg vial with 2 mL of bacteriostatic water, you get 2,500 mcg/mL. A 200 mcg target dose is then 200 ÷ 2,500 = 0.08 mL, which is 8 units on a standard U-100 insulin syringe (100 units = 1 mL). A calculator saves you from doing that arithmetic under a bathroom light at 6 a.m., and it reduces the chance of a decimal-point error, which is the single most common real-world dosing mistake with reconstituted peptides. It cannot tell you whether 200 mcg is the right number for you, because that number comes from the research literature, not from math. For the actual reconstitution steps, see reconstitute cjc ipamorelin.

What dose of ipamorelin has actually been studied in humans?

There's no single approved human dose because ipamorelin has never been through FDA approval as a standalone drug; it doesn't appear in the Drugs@FDA database of approved products. What exists instead is a scattered set of pharmacology and small clinical studies using different routes and doses for different purposes. The original 1998 paper describing ipamorelin as 'the first selective growth hormone secretagogue' characterized its receptor selectivity and GH-releasing activity in animal and in vitro systems, establishing it as a compound that stimulates GH release without significantly affecting cortisol, ACTH, or prolactin the way some other secretagogues do ^[1]. A 1999 pharmacokinetic-pharmacodynamic modeling study in human volunteers examined how ipamorelin blood levels related to GH release curves after dosing, which is the kind of data a calculator's 'starting dose' assumptions are quietly built on, even though the paper itself was modeling exposure-response, not defining a therapeutic label dose ^[2]. A nasal absorption study compared ipamorelin against other peptidyl GH secretagogues and found meaningful differences in bioavailability by route, which matters because a dose that works subcutaneously doesn't translate directly to nasal or oral delivery ^[3]. In the postoperative ileus trials, researchers used ipamorelin in a prospective, randomized, controlled proof-of-concept study in bowel resection patients, a completely different clinical context (GI motility, not body composition or anti-aging) with its own dosing schedule chosen for that indication ^[4]. None of this adds up to one 'correct' bodybuilding or anti-aging dose. It adds up to a set of dose-response relationships in specific study populations, for specific outcomes.

How do you calculate CJC-1295 dosage from a vial?

Same algebra as ipamorelin, different vial size and typically a different concentration target because CJC-1295 vials are often distributed at lower total mg than ipamorelin vials. Say you have a 2 mg CJC-1295 vial and you reconstitute with 2 mL of bacteriostatic water: that's 1,000 mcg/mL (1 mg/mL). A 100 mcg dose is then 0.1 mL, or 10 units on an insulin syringe. The practical wrinkle with CJC-1295 is that it exists in two structurally distinct forms discussed in the literature and in compounding contexts: one with a Drug Affinity Complex (DAC) modification that extends its half-life, and one without (sometimes called CJC-1295 without DAC, which is pharmacologically closer to modified GRF 1-29 / tetrasubstituted analogs used in receptor and structure-activity work) ^[5]. A calculator that doesn't ask which form you have is giving you a number that may not match the compound's actual half-life or intended dosing frequency. This is a formulation detail worth confirming with whoever dispenses the product before you touch a syringe. Because the two forms behave differently in duration of action, dosing frequency assumptions (once daily vs. a few times weekly) are not interchangeable between them, and no calculator can infer which one you're holding from the mg number on the label alone.

Is there a standard mcg-per-kg or mg-per-day dosage for ipamorelin?

No, and this is the honest, slightly unsatisfying answer. There is no regulatory-approved, weight-based mcg/kg dosing schedule for ipamorelin the way there is for, say, an approved pediatric growth hormone product. What you find in the literature are doses selected for specific study designs, not a generalizable per-kilogram formula for adults seeking body composition changes. Animal studies give a sense of dose-ranging work: a 1999 study found ipamorelin induced longitudinal bone growth in rats ^[6], a 2002 histology paper examined chronic ipamorelin treatment's effect on pituitary somatotroph cells in young female rats ^[7], and a 2001 study found ipamorelin counteracted glucocorticoid-induced decreases in bone formation in adult rats ^[8]. A related 2000 study found that ipamorelin and GHRP-6 increased bone mineral content in adult female rats ^[9]. These are real, useful mechanistic findings, but rat doses scaled by body surface area are not a substitute for a human clinical dosing guideline, and none of these papers were designed to establish a human daily dose. A 2020 review on GH secretagogues in hypogonadal men's body composition management discusses the physiological rationale for using GH secretagogues in this population, again without establishing one universal consumer dosing number ^[10]. If a calculator or a forum post gives you a single 'optimal' mcg/kg figure with total confidence, that confidence isn't coming from a controlled human dosing trial; it's coming from repetition of somebody's earlier guess.

How much CJC-1295 and ipamorelin should you use together (the stack question)?

This is where forum lore and actual evidence diverge hardest. The rationale for combining a GHRH analog (CJC-1295) with a ghrelin-mimetic GH secretagogue (ipamorelin) is mechanistic: they act on different receptors upstream of GH release, so in theory the combination could produce a bigger or more sustained pulse than either alone. That's a real pharmacological argument. It is not the same as a clinical trial showing a specific combined mcg dose produces a specific measured outcome in humans. Recent reviews addressing this exact evidence gap are blunt about it. A 2026 orthopaedic literature review on therapeutic peptides describes the state of applications, challenges, and future directions for peptides including GH secretagogues in orthopaedic contexts ^[11], while a 2026 American Journal of Sports Medicine primer on injectable peptide therapy is aimed specifically at helping sports medicine physicians understand what's studied versus what's marketed ^[12]. A 2026 Sports Medicine (Auckland) paper reviewing safety and efficacy of approved and unapproved peptide therapies for musculoskeletal injuries and athletic performance draws a direct line between FDA-approved peptide drugs and the much larger unapproved category that includes compounded ipamorelin and CJC-1295 combinations ^[13]. A 2026 JBJS Reviews narrative review on injectable peptides in sports medicine covers evidence, safety, and antidoping implications for this same category ^[14]. Read across all four, and the consistent message is: the receptor pharmacology behind a GHRH-plus-ghrelin-mimetic stack is plausible and mechanistically supported, but the specific dosing ratios circulating online (commonly something like 100 mcg of each, once or twice daily) are convention, not derived from a dose-finding trial in the population using them. If you want the actual dose ranges used in the trials that do exist, see ipamorelin dosage.

Does a CJC-1295 ipamorelin dosage calculator differ for a female user?

Mechanically, no. The mg-to-mL algebra is identical regardless of sex; a calculator converts units, it doesn't know or need to know who's injecting. What differs for women is the underlying question of what dose is appropriate, and here the honest answer is that dedicated female-specific human dosing trials for ipamorelin and CJC-1295 combinations are not part of the published literature reviewed here. Sex-specific pharmacokinetic differences in GH secretagogue response (body fat percentage, baseline GH pulsatility, hormonal cycling) are physiologically plausible reasons a dose might need adjusting, but none of the cited studies in this piece isolate female-specific dosing curves for these two compounds together. So when a search brings someone to 'cjc 1295 ipamorelin dosage calculator female,' the direct answer is: use the same conversion math, but treat any female-specific number you see quoted online as extrapolation, not established dosing. If a provider is overseeing your use, that individualized judgment (accounting for weight, goals, and any relevant labs) is exactly the layer a calculator cannot replace.

What's a typical injection volume for a 100 mcg or 200 mcg dose?

Once you know your concentration, the volume math is fast. Here's a reference table for common reconstitution setups, assuming a standard U-100 insulin syringe where 100 units equals 1 mL.

How stable is reconstituted ipamorelin, and does that affect dosing accuracy?

Yes, meaningfully, because a dosage calculator assumes the concentration you calculated at reconstitution is the concentration still in the vial weeks later, and peptide degradation can quietly break that assumption. A 2012 analytical chemistry paper on the metabolism of growth hormone releasing peptides examined how these compounds break down, which is directly relevant to shelf life and why refrigeration and use-by windows on compounded vials aren't arbitrary ^[15]. Separately, a 2015 drug testing analysis paper looked at growth hormone releasing peptide metabolites in human urine after nasal administration of several GHRPs, including ipamorelin, for anti-doping detection purposes; that's a different question (detection windows) but it reinforces that these peptides are metabolized on a real, measurable timescale in the body, not indefinitely stable ^[16]. Practically: if your vial has sat unrefrigerated, or past the stated use window, the mcg-per-click number your calculator gave you on day one may no longer match what's actually in the syringe on day thirty. No calculator corrects for degradation; it only does the math for the concentration you tell it.

Where do sourcing quality and black-market products fit into the dosing math?

They break the whole calculation before it starts. A dosage calculator assumes the vial actually contains the stated mg of the stated peptide at reasonable purity. A 2018 Growth Hormone & IGF Research analysis of new growth-promoting black market products found exactly the kind of quality and identity problems that make that assumption unsafe with unregulated sources ^[17]. If a vial is mislabeled, underdosed, or contaminated, every downstream calculation, however careful, is built on a false input. This is the practical argument for sourcing through a provider-reviewed pathway rather than an anonymous online vendor: the calculator can only be as accurate as the label it's reading. See buy ipamorelin for what a legitimate sourcing pathway looks like, and note the product reality up front: there is no standalone retail ipamorelin vial in the reputable supply chain we'd point you to. Ipamorelin is dispensed as part of a tesamorelin/ipamorelin blend, which changes the concentration math again (you're now calculating two peptide concentrations from one vial, not one).

Where does a tesamorelin/ipamorelin blend change the calculator math?

A blended vial has two active peptides at two different mg totals in the same diluent volume, so you need two concentration numbers, not one. If a blend vial contains, say, 10 mg tesamorelin and 5 mg ipamorelin in 2 mL of bacteriostatic water, tesamorelin concentration is 5,000 mcg/mL and ipamorelin concentration is 2,500 mcg/mL, and one injection volume delivers both doses simultaneously in that fixed ratio. You can't independently titrate one peptide up without also changing the other; the ratio is locked at manufacture. This matters for anyone comparing a tesamorelin/ipamorelin blend against a straight CJC-1295/ipamorelin combination, because the two aren't interchangeable pharmacologically (tesamorelin is itself a GHRH analog, structurally distinct from CJC-1295, and it's the one GH secretagogue-adjacent peptide with actual FDA-approved status, for HIV-associated lipodystrophy). If you're deciding between the two approaches, ipamorelin vs tesamorelin walks through that comparison directly. Ipamorelin Co works within this reality: it dispenses ipamorelin exclusively as part of a tesamorelin/ipamorelin blend, and any provider-reviewed order should specify that blend ratio explicitly rather than assuming a generic 'ipamorelin dose' translates directly.

What side effects should influence how you adjust a dose?

Dose adjustment decisions in real practice are driven by tolerability signals, more than a target number on a calculator. Injection site reactions, water retention, flushing, and headache are the commonly reported issues with GH secretagogues broadly, and a 2026 International Journal of Molecular Sciences review of therapeutic peptides in aesthetic, metabolic, and endocrine conditions covers effects and safety considerations across this peptide class ^[18]. A 2026 Frontiers in Aging review on therapeutic peptides in gerontology looks at mechanisms and applications specifically in the context of aging-related use cases, which is the population most likely to be using these compounds long-term ^[19]. On the mechanistic safety side, a 2001 paper found GH secretagogues can stimulate adiposity through a GH-independent pathway in some models ^[20], and a 2004 paper examined the mechanism of ipamorelin-evoked insulin release from the pancreas in normal and diabetic rats, relevant to anyone with glucose regulation concerns ^[21]. None of these are reasons to panic, but they're reasons a 'just take more, more is better' approach to dose calculators is the wrong instinct. If you notice new symptoms after a dose change, that's information a spreadsheet can't weigh for you. Full side effect detail is at ipamorelin side effects.

Is it legal to buy compounded CJC-1295 or ipamorelin for dosing at home?

This is a regulatory gray zone, and the calculator question can't be separated from it. Compounding pharmacies operate under 21 U.S.C. § 353a, which permits pharmacist compounding of drugs for identified patients under specific conditions ^[22]. FDA maintains bulk drug substance lists under 21 CFR 216.23 (the 503A bulks list, for pharmacy compounding) ^[23] and 21 CFR 216.24 (the 503B bulks list, for outsourcing facilities) ^[24], and FDA's own guidance page on bulk drug substances for 503A compounding explains how substances get evaluated for inclusion ^[25]. Whether a given peptide is on an approved bulks list at any given time is a live, moving target, and FDA separately maintains a list of substances nominated for compounding consideration ^[26]. Neither CJC-1295 nor ipamorelin is an FDA-approved drug in its own right; you can confirm that by checking Drugs@FDA, the agency's approved drug products database, directly ^[27]. That means any compounded version exists through the 503A/503B pharmacy framework, not through standard drug approval, and the legal footing depends on the compounder following that framework correctly, including individualized prescribing rather than mass production for anticipated demand. This is a genuinely good reason to route sourcing through a provider relationship rather than a direct-to-consumer vial from an unverified seller.

Frequently asked questions

How do I calculate my CJC-1295 or ipamorelin dose from a vial in mg?

Divide the vial's total mcg by the mL of bacteriostatic water you added; that gives concentration in mcg/mL. Then divide your target dose (mcg) by that concentration to get injection volume in mL. Multiply mL by 100 to get insulin syringe units. Example: 5 mg in 2 mL = 2,500 mcg/mL; a 200 mcg dose is 0.08 mL, or 8 units.

Is there an official recommended dose for ipamorelin or CJC-1295?

No. Neither compound is FDA-approved as a standalone drug, confirmable via the Drugs@FDA database, so there's no approved-label dosing schedule. Published research uses varied doses for varied purposes, from postoperative ileus trials to receptor pharmacology studies, none of which establishes one universal consumer dose.

What's a typical starting dose people use for ipamorelin?

Commonly cited ranges in practice fall around 100 to 300 mcg per injection, but this figure comes from convention and provider experience, not a single dose-finding human trial establishing an optimal number. Any provider-guided plan should account for your goals and health history rather than a flat forum-sourced figure.

Does a CJC-1295 ipamorelin dosage calculator work differently for women?

The unit-conversion math is identical for any user. What may differ is the appropriate target dose itself, and no study in the current literature isolates female-specific dosing curves for this combination. Treat sex-specific dosing claims found online as extrapolation rather than established science.

Can I buy ipamorelin as a standalone peptide?

Not through a reputable, provider-reviewed pathway. Ipamorelin is dispensed as part of a tesamorelin/ipamorelin blend rather than sold alone, which changes the concentration math since one vial carries two peptide totals in the same diluent volume.

How long does reconstituted CJC-1295 or ipamorelin stay stable?

Peptide degradation is a real, measurable process studied in analytical chemistry work on GH-releasing peptide metabolism. Refrigeration and adherence to a compounder's stated use-by window matter because your dosage calculator's concentration figure is only accurate for as long as the peptide hasn't broken down.

Why do CJC-1295 and ipamorelin get stacked together?

The mechanistic rationale is that CJC-1295 (a GHRH analog) and ipamorelin (a ghrelin-mimetic secretagogue) act on different upstream receptors, so combining them could amplify the GH pulse beyond either alone. That's a plausible pharmacology argument; it isn't backed by a controlled human trial establishing an optimal combined dose.

Is CJC-1295 with DAC dosed the same as CJC-1295 without DAC?

No. The DAC modification extends the compound's half-life, which changes dosing frequency assumptions considerably. A calculator that doesn't distinguish which form you have can give you a mathematically correct volume for the wrong dosing schedule, so confirm the specific form with your dispensing source.

What syringe should I use to measure small mcg doses accurately?

Standard U-100 insulin syringes, marked in units where 100 units equals 1 mL, are the typical tool because they allow precise measurement of small volumes like 0.04 to 0.10 mL. Reading the markings correctly matters more than the calculator itself for avoiding real-world dosing errors.

Are there safety risks specific to higher CJC-1295/ipamorelin doses?

Mechanistic studies note GH secretagogues can affect adiposity through GH-independent pathways and can influence pancreatic insulin release, which is relevant for anyone with glucose regulation concerns. These are reasons to avoid simply escalating dose without provider input rather than reasons for alarm at typical low-mcg doses.

Is it legal to get a compounded CJC-1295/ipamorelin prescription in the US?

Compounding is legal under 21 U.S.C. § 353a when a licensed pharmacy compounds for an identified patient following FDA's bulk drug substance framework under 21 CFR 216.23 and 216.24. Neither peptide is independently FDA-approved, so legality depends on the compounder correctly following that regulatory pathway.

Does a dosage calculator account for peptide purity or quality?

No, and this is a real limitation. A calculator assumes the vial contains exactly the labeled mg at reasonable purity. Analysis of black-market growth-promoting products has found quality and labeling problems in unregulated sources, meaning the calculator's output is only as trustworthy as the vial's actual contents.

Sources

1. European Journal of Endocrinology, 1998 (PMID 9849822): Describes ipamorelin as the first selective growth hormone secretagogue, characterizing its receptor selectivity versus cortisol/ACTH/prolactin effects.
2. Pharmaceutical Research, 1999 (PMID 10496658): Pharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers relating blood levels to GH release.
3. Xenobiotica, 1998 (PMID 9879640): Pharmacokinetic evaluation of ipamorelin and other peptidyl GH secretagogues, with emphasis on nasal absorption and route-dependent bioavailability differences.
4. International Journal of Colorectal Disease, 2014 (PMID 25331030): Prospective randomized controlled proof-of-concept study used ipamorelin for postoperative ileus management in bowel resection patients.
5. Journal of Medicinal Chemistry, 1998 (PMID 9733495): Describes a series of highly potent growth hormone-releasing peptides derived from ipamorelin, relevant to structural variants and analogs.
6. Growth Hormone & IGF Research, 1999 (PMID 10373343): Found ipamorelin induces longitudinal bone growth in rats.
7. Histology and Histopathology, 2002 (PMID 12168778): Examined chronic ipamorelin treatment's effect on pituitary somatotroph cells in young female rats.
8. Growth Hormone & IGF Research, 2001 (PMID 11735244): Found ipamorelin counteracts glucocorticoid-induced decreases in bone formation in adult rats.
9. The Journal of Endocrinology, 2000 (PMID 10828840): Found ipamorelin and GHRP-6 increase bone mineral content in adult female rats.
10. Translational Andrology and Urology, 2020 (PMID 32257855): Reviews the physiological rationale for GH secretagogues in body composition management in hypogonadal men.
11. Journal of the American Academy of Orthopaedic Surgeons Global Research & Reviews, 2026 (PMID 41490200): Reviews applications, challenges, and future directions of therapeutic peptides in orthopaedics.
12. American Journal of Sports Medicine, 2026 (PMID 41476424): Provides a primer for orthopaedic and sports medicine physicians on injectable peptide therapy.
13. Sports Medicine (Auckland), 2026 (PMID 41966639): Reviews safety and efficacy of approved versus unapproved peptide therapies for musculoskeletal injuries and athletic performance.
14. JBJS Reviews, 2026 (PMID 42160466): Structured narrative review covering evidence, safety, and antidoping implications of injectable peptides in sports medicine.
15. Analytical Chemistry, 2012 (PMID 23101768): Studies the metabolism of growth hormone releasing peptides, relevant to degradation and stability.
16. Drug Testing and Analysis, 2015 (PMID 25869809): Determined GH-releasing peptide metabolites in human urine after nasal administration of several GHRPs including ipamorelin.
17. Growth Hormone & IGF Research, 2018 (PMID 29864719): Analysis of new growth-promoting black market products found quality and identity problems in unregulated sources.
18. International Journal of Molecular Sciences, 2026 (PMID 42123471): Reviews effects and safety of therapeutic peptides in aesthetic, metabolic, and endocrine conditions.
19. Frontiers in Aging, 2026 (PMID 42021992): Reviews mechanisms and applications of therapeutic peptides in gerontology and healthy aging.
20. Biochemical and Biophysical Research Communications, 2001 (PMID 11162489): Found GH secretagogues can stimulate adiposity through a GH-independent mechanism.
21. Neuro Endocrinology Letters, 2004 (PMID 15665799): Examined the mechanism of ipamorelin-evoked insulin release from the pancreas in normal and diabetic rats.
22. 21 U.S.C. § 353a, pharmacy compounding: Establishes the legal framework permitting pharmacist compounding of drugs for identified patients under specific conditions.
23. 21 CFR 216.23, the 503A Bulks List: Lists bulk drug substances that may be used in compounding under section 503A.
24. 21 CFR 216.24, the 503B Bulks List: Lists bulk drug substances that may be used in compounding by 503B outsourcing facilities.
25. FDA, bulk drug substances used in compounding under section 503A: Explains FDA's process for evaluating bulk drug substances proposed for use in 503A compounding.
26. FDA, bulk drug substances nominated for use in compounding (current list): Maintains the current list of substances nominated for consideration in compounding.
27. Drugs@FDA, FDA-approved drug products database: Confirms neither CJC-1295 nor ipamorelin appears as an independently FDA-approved drug product.